I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

The incidence of diabetes in Libya is estimated to be 8.9%.\[[@ref1]\] Fear of hypoglycaemia and gain in body weight are barriers for initiation of insulin therapy.\[[@ref2]\] Modern insulin analogues are a convenient new approach or tool to glycaemic control, associated with low number of hypoglycaemia and favourable weight change.\[[@ref3]\] A~1~chieve, a multinational, 24-week, non-interventional study, assessed the safety and effectiveness of insulin analogues in people with T2DM (*n* = 66,726) in routine clinical care.\[[@ref4]\] This short communication presents the results for patients enrolled in biphasic insulin aspart sub group from Libya.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Please refer to editorial titled: The A~1~chieve study: Mapping the Ibn Battuta trail. The study was started with an aim to collect data on all the insulin analogue viz insulin detemir, biphasic insulin aspart and insulin aspart. However, due to ongoing revolution, the complete data could not be collected. Here we present the data for biphasic insulin aspart subgroup.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 316 patients were enrolled in the study. The majority of patients (189) were started on or were switched to Biphasic insulin aspart. Other groups were insulin detemir (*n* = 58), basal + insulin aspart (*n* = 44) and other insulin combinations (*n* = 25). Being the biggest treatment group, this communication describes the results for patients treated with insulin therapy before and then switched to biphasic insulin aspart.

The patient characteristics for biphasic insulin aspart subgroup are shown in the [Table 1](#T1){ref-type="table"}. Glycaemic control at baseline was poor in this population.

###### 

Overall demographic data
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Safety data {#sec2-1}
-----------

179 patients started on biphasic insulin aspart ± OGLD, and all the patients were on insulin therapy prior to the study. After 24 weeks of switching to biphasic insulin aspart, hypoglycaemic events reduced from 7.2 events/patient-year to 3.7 events/patient-year \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].

###### 

Overall safety data
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###### 

Insulin dose
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Efficacy data {#sec2-2}
-------------

All parameters of glycaemic control improved from baseline to study end \[[Table 4](#T4){ref-type="table"}\].

###### 

Overall efficacy data

![](IJEM-17-435-g004)

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

Our study reports improved glycaemic control following 24 weeks of treatment with biphasic insulin aspart with or without OGLD. Hypoglycemic events decreased from baseline and SADRs did not occur in any of the study patients. A small increase in body weight was observed. Though the findings are limited by number of patients, still the trend indicates that biphasic insulin aspart can be considered effective and possess a safe profile for treating type 2 diabetes in Libya.
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